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Running title: Interactions between TDP-43 C-terminal domain and GRNs

INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a
neurodegenerative disorder characterized by
progressive changes in behavior, speech, and
personality among elderly patients (1,2). These
changes are bought upon by a gradual atrophy of
the frontal and anterior temporal lobes of the brain
(3-6). Based on histopathology, heritable FTLD can
be classified into the following subtypes: FTLDTDP form, which is characterized by the presence
of cytoplasmic inclusions of TAR DNA binding
protein-43 (TDP-43), and which constitutes about
half of all cases of FTLD (7); FTLD-Tau in which
2
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cytoplasmic inclusions of hyperphosphorylated tau
are observed, and FTLD-FUS, which is associated
with inclusions of an RNA-binding protein called
fused in sarcoma (FUS) (8-12). The FTLD-TDP
pathology is further sub-classified based on genetic
and clinical presentation (13). Autosomal dominant
mutations to progranulin gene (PGRN) are
associated with type A while the hexanucleotide
repeat expansions in C9orf72 are present in type B
cases (13). Inclusions of TDP-43 are also observed
in patients with ALS (14-16). In addition to
mutations in TDP-43, those in several genes have
been linked to ALS including FUS, superoxide
dismutase 1 (SOD1) and hexanucleotide repeat
expansions in C9orf72. Since TDP-43-based
neuropathology is present in ~50% of FTLD and
~97% of ALS cases (17), the protein represents a
molecular link connecting these neurodegenerative
diseases as a clinicopathological spectrum of the
proteinopathies (15,18-20). It has also come to light
that TDP-43 may contribute to the pathogenesis of
Alzheimer disease (AD) via both β-amyloid (Aβ)
dependent and independent pathways (21).
Furthermore, TDP-43 abnormalities have also been
associated with traumatic brain injury (chronic
traumatic encephalopathy) in both pre-clinical and
clinical studies (7), and observed in cognitively
impaired persons in advanced age with
hippocampal sclerosis, Huntington's disease and
some other maladies (22). Due to the widespread
prevalence of TDP-43 in neurodegenerative
pathogenesis, all abnormalities involving the
protein are classified into the category of ‘TDP-43
proteinopathies’ (22,23).
TDP-43 is a member of the heterogenous
ribonucleoprotein
family
involved
in
transcriptional regulation and mRNA splicing in
neurons (24). The protein consists of an N-terminal
domain, two RNA recognition motifs (RRMs)
followed by a low-complexity, glycine-rich Cterminal domain (25). The protein is known to
dimerize through the N-terminal domain, while
specific phosphomimic mutants within this domain
disrupt its aggregation, liquid-liquid phase
separation (LLPS) and RNA splicing activity
(26,27). Although mainly localized in the nucleus,
in the diseased state, a fraction of the full-length
TDP-43 is proteolytically cleaved and thus
generated 25 and 35 kDa (C25 and C35) C-terminal
fragments are transported into the cytoplasm. These
fragments form toxic insoluble inclusions observed

ABSTRACT
Tar DNA binding protein 43 (TDP-43) has
emerged as a key player in many neurodegenerative
pathologies including frontotemporal lobar
degeneration (FTLD) and amyotrophic lateral
sclerosis (ALS). Hallmarks of both FTLD and ALS
are the toxic cytoplasmic inclusions of the prionlike C-terminal fragments of TDP-43 (TDP-43
CTD), formed upon proteolytic cleavage of fulllength TDP-43 in the nucleus and subsequent
transport to the cytoplasm. Both full-length TDP43 and its CTD are also known to form stress
granules (SGs) by coacervating with RNA in the
cytoplasm during stress and may be involved in
these pathologies. Furthermore, mutations in PGRN
gene, leading to haploinsufficiency and diminished
function of progranulin (PGRN) protein, are
strongly linked to FTLD and ALS. Recent reports
have indicated that proteolytic processing of PGRN
to smaller protein modules called granulins (GRNs)
contributes to FTLD and ALS progression, with
specific GRNs exacerbating TDP-43–induced
cytotoxicity. Here, we investigated the interactions
between the proteolytic products of both TDP-43
and PGRN. Based on structural disorder and charge
distributions, we hypothesized that GRNs -3 and -5
could interact with TDP-43 CTD. We also show
that in both reducing and oxidizing conditions
GRNs -3 and -5 interact with and differentially
modulate TDP-43 CTD aggregation and/or liquidliquid phase separation (LLPS) in vitro. While
GRN-3 promoted insoluble aggregates of TDP-43
CTD, GRN-5 mediated LLPS. These results
constitute the first observation of an interaction
between GRNs and TDP-43, suggesting a
mechanism by which attenuated PGRN function
could lead to familial FTLD or ALS.

observation that GRN-3 is active in both reduced
and oxidized forms (58,59). Furthermore, GRNs’
presence in both extra- and intracellular space led
us to hypothesize that they may play a role under
redox fluctuations. Here, we specifically
investigated whether GRNs -3 and -5 are able to
modulate LLPS or formation of insoluble
inclusions of TDP-43 CTD, which shed insights
into the potential role of GRNs in FTLD and ALS
pathologies.
RESULTS
Structural disorder and charge distribution
among GRNs and TDP-43 CTD suggest potential
interactions. The 14.5 kDa construct of TDP-43
that constitutes residues 267-414 in the C-terminal
domain (TDP-43 CTD) is a major part of the C25
proteolysis fragment that forms aberrant inclusions
within the cytosol in FTLD and ALS patients (Fig
1a)(16). Fig 1b shows that TDP-43 CTD is largely
disordered, and previous study indicated that this
protein contains sequence of low-complexity that is
involved in LLPS (60). On the other hand, GRNs
(1-7) are small ~ 6 kDa proteins with the conserved
sequence;
X2-3CX5-6CX5CCX8CCX6
CCXDXXHCCPX4CX5-6CX (Fig 1a). The 12
conserved cysteine residues form six putative
intramolecular disulfide bonds (61) (Fig 1a). Fig 1c
and Fig 1d show that despite the fact that these
proteins contain high levels of cysteine, which is
the strongest order-promoting residue, GRN-3 and
GRN-5 are predicted to be characterized by high
levels of disorder. This is in line with the results of
our previous studies, where we have shown that
under reducing conditions, GRN-3 is fully
disordered while in the oxidizing conditions, the
protein obtains thermal stability via disulfide bonds
without significant gain in the overall structure
(59,62).
As a first step in understanding the effect of
GRNs on TDP-43, here we report the interactions
of GRNs 3 and 5 with TDP-43 CTD in both
reducing and oxidizing conditions. GRN-5 was
expressed and purified using the established
method for GRN-3 (59) with some minor
modifications (see Experimental Procedures). As
observed previously with GRN-3 (59,62), we
observed that GRN-5 too, in both reducing and
oxidizing conditions, show a random coil
disordered structure (Supplementary information;
Fig S1). Intrinsic disorder predisposition of TDP3
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in ALS and FTLD-TDP patients (19,28,29). Under
stress, both full-length and TDP-43 C-terminal
fragments are also known to bind RNA and
translocate to the cytosol, where they undergo
LLPS to form the membraneless organelles called
stress granules (29). LLPS has been increasingly
observed in many cellular systems and are thought
to be important in modulating many cellular
functions (30-39). The precise mechanism of stress
granule dynamics in TDP-43 pathophysiology
remains unclear but many proteins are known to
interact with, and partition into the phase separated
droplets of TDP-43 (40,41). In FTLD and ALS, the
aberrant LLPS of TDP-43 has emerged as a driving
factor for the aggregation of the protein (40,42,43).
Progranulin (PGRN) is a 63.5 kDa secreted
protein expressed in many cells including the
neurons and in microglia (44-46), with pleiotropic
roles in both physiological and pathological
processes (47-51). The protein consists of seven
and a half cysteine-rich modules called granulins
(GRNs) (Fig 1a) (47,49,52-54), which are
generated by proteolytic processing of PGRN by
many proteases. PGRN and GRNs are observed to
co-exist in vivo with opposing inflammatory
functions (55). In FTLD, the observed inclusions of
TDP-43 C-terminal fragments occur in the genetic
backdrop of autosomal dominant, heterozygous
mutations of PGRN that leads to haploinsuffiency
of the PGRN protein. Homozygous PGRN
mutations on the other hand lead to neuronal ceroid
lipofuscinosis (NCL), a lysosomal storage disease
(56). The production of GRNs in haploinsufficient,
but not the null state in FTLD, suggests that they
are key players in the disease phenotypes. This also
indicates that the extenuation of PGRN function
could arise from its increased proteolytic
processing to generate GRNs (55). Indeed, GRNs
are shown to interact with TDP-43 and exacerbate
latter’s levels and toxicity in C.elegans,
establishing that PGRN cleavage to GRNs could
represent an important part of the disease process in
FTLD (57). Despite the growing evidence on the
involvement of GRNs, their precise mechanisms in
FTLD and related pathologies remain unclear. In
this report, we sought to understand the interactions
between GRNs and TDP-43 CTD, both of which
are proteolytic products of their precursors, under
reducing and oxidizing conditions in vitro. Our
premise for investigations under reducing and
oxidizing conditions stems from our previous
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GRN-3, and GRN-5 were 3.88, -3.06, and -2.83,
respectively, indicating that only TDP-43 CTD has
an intrinsic propensity for granule formation
associated to liquid demixing under the
physiological conditions. It has to be borne in mind
that the positive CatGRANULE score for TDP43CTD can be attributed to the fact that the
algorithm was trained on the TDP-43 sequence.
However, the negative CatGRANULE scores for
GRNs are independent and decoupled to the use of
TDP-43 sequence for the algorithm training.
GRN-5 but not GRN-3 initiates LLPS of TDP43 CTD. To see whether GRNs mediate TDP-43
CTD phase separation, the two proteins were coincubated in 2:1 molar ratio respectively, and the
samples were monitored for turbidity increase and
droplet formation by differential interference
contrast (DIC) microscopy in both oxidizing
(GRN-3 or GRN-5) and reducing (rGRN-3 or
rGRN-5) conditions (Fig 2). At room temperature,
20 µM TDP-43 CTD buffered in 20 mM MES at
pH 6.0 without salt in presence of 40 µM of GRN5 or rGRN-5 formed a turbid solution instantly,
similar to the known phase separation shown by
TDP-43 CTD-RNA mixture (Fig 2a). On the other
hand, incubation of TDP-43 CTD by itself or with
40 µM of GRN-3 or rGRN-3 did not show turbidity
(Fig 2a). To define the phase boundaries of LLPS
by TDP-43 CTD by under increasing GRN
concentrations, 20 µM TDP-43 CTD was
incubated with GRN-3, rGRN-3, GRN-5 and
rGRN-5 in the absence of salt (Fig 2b). Both GRN5 and rGRN-5 induce LLPS at concentrations as
low 10 µM while neither GRN-3 nor rGRN-3 failed
to induce any LLPS even at high concentrations
(Fig 2b). Next, phase boundaries of TDP-43 CTD
LLPS as a function of GRN concentration and ionic
strength were determined (Fig 2c-g). TDP-43 CTD
control in the absence of GRNs but with increasing
NaCl concentrations showed no LLPS below the
physiological concentration of 150 mM salt (Fig
2c). GRN-3 showed LLPS above 100 mM NaCl
over a large GRN concentration range (Fig 2d).
rGRN-3 showed LLPS under relatively a narrow
range of salt concentrations above 300 mM (Fig
2e). Both GRN-5 and rGRN-5 induced LLPS over
a broad range of GRN and salt concentrations (Fig
2f-g). Only low GRN concentration and low ionic
strength failed to induce LLPS of TDP-43 CTD.
To visualize LLPS, the samples were observed

43 and four other proteins (superoxide dismutase 1
(SOD1), FUS, a cofilin-binding protein C9orf72,
and polypeptides generated as a result of its intronic
hexanucleotide expansions, and actin-binding
profilin-1 (PFN1)), which are considered as the
major drivers of ALS and FTLD pathogenesis,
recently revealed significant levels of disorder
among these proteins (63,64). Here, we set out to
determine whether disorder and charge distribution
among TDP-43 CTD, and GRNs indicate
interaction propensities. The primary sequence of
GRN-5 is enriched in negatively charged residues
and lack positively charged residues with a net pI
of 4.01. On the other hand, TDP-43 CTD has an
appreciable number of positively charged amino
acids with a net pI of 9.52 (Fig 1a). The computed
disorder predispositions show high degree of
disorder for entire sequence of TDP-43 CTD
(values > 0.5; Fig 1b), while GRN-3 and GRN-5
show disordered regions in both N- and C-terminal
regions (Fig 1c and 1d). The linear net charge per
residue (NCPR) plots for these proteins generated
by CIDER computational platform (65) show that
positively charged residues are preferentially
concentrated within the 50 N-terminal residues of
TDP-43 CTD (Fig 1e), whereas negatively charged
residues are distributed over the entire sequence of
GRN-5 (Fig 1g). Importantly, ANCHOR analysis
(66,67) of the TDP-43 CTD construct utilized in
this study revealed the existence of several
disorder-based binding regions (residues 1-40, 6699, 115-123, and 135-145). These regions represent
molecular recognition features (MoRFs), which are
intrinsically disordered segments that undergo
folding on interaction with specific binding
partners. Based on the counter-ionic character of
the two proteins, we hypothesize that GRN-5 could
interact with TDP-43 CTD and mediate LLPS. In
addition, GRN-3 was chosen to test our hypothesis
as this protein is also intrinsically disordered and
has a pI of 5.33, but it contains both positive and
negatively charged residues (Fig 1a and Fig 1f).
We also checked the amino acid sequencebased predispositions of TDP-43 CTD, GRN-3, and
GRN-5 to undergo LLPS. To this end, the
CatGRANULE algorithm was utilized that predicts
LLPS propensity based on the analysis of the phase
separation features linked to its primary sequence
composition, structural disorder, and nucleic acid
binding propensities (68). This analysis indicated
that the CatGRANULE scores for TDP-43 CTD,

increase in ThT fluorescence for all stoichiometric
incubations (Fig 3a; inset). These data suggest that
GRN-3 and GRN-5 interact with TDP-43 CTD
differently to modulate latter’s aggregation.
Furthermore, the observed instantaneous LLPS of
TDP-43 CTD in the presence of GRN-5 and rGRN5 (Fig 2) raises the possibility of the ThT dye
partitioning into the droplets formed, resulting in
the higher ThT fluorescence observed. To
investigate this, the reactions were visualized by
fluorescence microscopy using another amyloid
binding dye called thioflavin-S (ThS). Both ThT
and ThS are known to detect amyloid aggregates
(73,74). A 10 µM buffered solution of ThS was
added to the samples containing 20 µM TDP-43
CTD alone (Fig 3i) and in the presence of 40 µM
GRNs; GRN-3 (Fig 3e), rGRN-3 (Fig 3f), GRN-5
(Fig 3g), and rGRN-5 (Fig 3h). Instantaneously
upon addition, TDP-43 CTD alone and with either
GRN-3 or rGRN-3 showed no aggregate formation,
and a disperse blue fluorescent haze was observed
(Fig 3i , Fig 3e and Fig 3f; 0h). It has to be noted
that the use of a 420-480 nm band pass emission
filter generates a blue color to ThS. The same
reactions after 36 hours showed more concentrated
areas where ThS was observed that coincided with
the presence of inclusions (Fig 3i, Fig 3e and Fig
3f; 36h). GRN-5 or rGRN-5 on the other hand,
showed the presence of ThS within the droplets
even at 0 hours (Fig 3g and Fig 3h; 0h), which
continued to be present even after 36 hours (Fig 3g
and Fig 3h; 36h). These data suggest that, a) ThS
(or ThT) could partition into the droplets, b)
enhanced fluorescent signals could emerge due to
partitioning into the droplets, and c) a small amount
of ThT-positive species could be present within the
droplets.
Both GRNs colocalize with TDP-43 CTD
within the droplets or aggregates. To probe
whether the droplets are complex coacervates of
TDP-43 CTD and GRNs or formed without GRNs’
partitioning into the separated phase, fluorescence
microscopy was used to observe the colocalization
of the two proteins. TDP-43 CTD and GRNs,
labeled with HiLyte 647 and HiLyte 405,
respectively, were incubated separately under
oxidizing and reducing condition and monitored for
36 hours (Fig 4). As expected, TDP-43 CTD by
itself did not form phase separated droplets
immediately after incubation (Fig 4a; 0h), and over
the next 36 hours, sparse deposits of aggregated
5
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under a DIC microscope for 2:1 co-incubations of
GRN:TDP-43 CTD in the same buffer conditions
as mentioned above. The TDP-43 CTD control
along with the mixture containing GRN-3 or rGRN3 did not show the formation of liquid droplets for
up to 6 hours (Fig 2h). In contrast, liquid droplets
were observed almost instantaneously when TDP43 CTD was co-incubated with rGRN-5, GRN-5 or
RNA (Fig 2h). The droplets that were numerous
and small initially, grew in size by coalescing with
one another in the next six hours of incubation,
displaying fluid-like characteristics. Together, the
data suggest GRN-5 or rGRN-5, and not GRN-3 or
rGRN-3, is able to initiate/enhance the phase
separation of TDP-43 CTD significantly at low salt
concentrations.
GRNs -3 and -5 differently modulate the LLPS
and formation of ThT-positive aggregates of TDP43 CTD. In FTLD and ALS pathologies, TDP-43
CTD is known to form toxic inclusions in the
cytosol. Yet, ambiguity remains regarding the
nature of these inclusions, with the presence of both
thioflavin-T (ThT)-positive and ThT-negative
aggregates has been reported (69-72). To see how
GRNs affected the formation of TDP-43 CTD
inclusions, we monitored ThT fluorescence for
TDP-43 CTD samples in the presence of increasing
concentrations of GRN-3, rGRN-3, GRN-5, or
rGRN-5 at 37 °C (Fig 3). The sample of 20 µM
TDP-43 CTD alone in 20 mM MES buffer at pH
6.0 showed a typical sigmoidal increase in
fluorescence with a lag time of ~ 8 hours (l; Fig 3)
indicating the formation of ThT-positive species.
For
GRN-3
incubations,
increasing
its
stoichiometry from 0.1 to 4-fold excess to that of
TDP-43 CTD showed increasing lag time of
aggregation (Fig 3a). The 0.1-fold incubation
showed the smallest lag time with 12 hours, while
the 4-fold excess GRN-3 showed the highest lag
time of ~22 hours. Similarly, under fully reducing
conditions, 0.1 to 4-fold excess of rGRN-3 also
inhibited TDP-43 CTD aggregation, but to a much
lesser degree than GRN-3, with lag times ranging
between 8 and 15 hours (Fig 3b). Similarly,
incubation of GRN-5 in increasing concentrations
(0.1 to 4-fold excess) with TDP-43 CTD showed an
overall inhibition of the TDP-43 CTD fibrillation
by increasing the lag times (12 to 36 hours,
respectively) (Fig 3c). Incubations of rGRN-5 with
TDP-43 CTD, on the other hand, showed no
discernable lag time but an instantaneous linear
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To further confirm and quantify the partitioning
and co-localization of TDP-43 CTD and GRNs, the
relative amounts of the proteins within the droplets
as well as the deposits were quantified by MALDITOF mass spectrometry. Using a known amount of
insulin (6.45 ng/µL) as an external standard, the
mass spectra were obtained (Figs 5a-e) and the
relative quantities of the proteins were calculated
and normalized (detailed in Materials and
Methods). Aliquots of the samples used in Fig 3 and
Fig 4 were obtained after 36 hours for quantitative
analysis. Both GRN-3 and rGRN-3 showed positive
correlation between the amount of GRN coincubated and TDP-43 CTD with the amount of
GRN-3 or rGRN-3 increasing in the sedimented
pellet with increase in GRN:TDP-43 CTD molar
ratios (Fig 5f and Fig 5g). More importantly, the
ratio of GRN to TDP-43 CTD intensities remained
below one, suggesting GRN-3 or rGRN-3 may
augment TDP-43 CTD aggregation by nucleating
and not by forming a co-complex in stochiometric
proportions. This observation is similar to the
recently observed ability of GRN-3 and rGRN-3 to
form fibrils of amyloid-b(1-42) (Ab42) peptide
involved in Alzheimer disease (AD), where
minimal GRN was observed in the pellet (58). On
the other hand, the ratio of GRN-to-TDP-43 CTD
obtained from the sedimented droplets of TDP-43
CTD and GRN-5 or rGRN-5 co-incubations did not
show a linear increase with increasing
concentrations of GRN as observed with GRN-3
(Fig 5h and Fig 5i). For co-incubations of GRN-5
and rGRN-5, the GRN-to-TDP-43 CTD ratio
remained at 0.75 and 1.1, respectively, over the
entire range of molar ratios. It is known that the
phenomenon of coacervation is dependent on a
defined valency of interactions among the
molecules which remain fixed within the dense
phase (75-78). One could speculate that the network
of weak interactions necessary to stabilize the TDP43 CTD droplets could be achieved by
accommodating equimolar proportions of GRN-5
or rGRN-5 within the droplets.
GRNs modulate liquid droplets formed by
TDP-43 CTD and RNA. One of the main aspects of
TDP-43 pathobiology is the coacervation with
RNA molecules to form membraneless organelles
in the form of stress granules (79-81). To see
whether GRNs 3 and 5 are able to interact with, and
modulate liquid droplets (LDs) of TDP-43 CTD
and RNA, torula yeast RNA extract was co-

protein were observed (Fig 4a; 18h and 36h). Coincubations of GRN-3 or rGRN-3 with TDP-43
CTD showed no LLPS immediately after
incubation (Fig 4b and Fig 4c; 0h), parallel to the
observation by DIC and turbidity (Fig 2). Even
after 36 hours, no phase separated liquid droplets,
but insoluble, fibrillar deposits were observed (Fig
4b and Fig 4c; 18h and 36h) that bind amyloid dyes
as shown above (Fig 3). Moreover, the GRNs were
observed to be localized in the vicinity of TDP-43
CTD deposits as well as within them (Fig 4b and
Fig 4c; 36h). On the other hand, co-incubations of
both GRN-5 and rGRN-5 with TDP-43 CTD
resulted in the emergence of well-defined liquid
droplets immediately after incubation (Fig 4d and
Fig 4e; 0h). The number of droplets increased
during the next 36 hours of incubation, with some
becoming more distorted spherical droplets (Fig 4d
and Fig 4e; 18h and 36h). Importantly, both GRNs
(blue) colocalize within the droplets formed by
TDP-43 CTD (red). To further glean into the
physical nature of the droplets or insoluble
inclusions formed, fluorescence recovery after
photobleaching (FRAP) was conducted (Fig 4f-j).
After 36h of incubation, TDP-43 CTD control
showed no recovery after bleaching indicative of
insoluble solid nature of the aggregates (Fig 4f). A
similar behavior was observed with the
coincubations of TDP-43 CTD with GRN-3 or
rGRN-3 (Fig 4g and 4h) suggesting that GRN-3 in
both reducing and oxidized states promoted
insoluble fibrils of TDP-43 CTD as seen from the
microscopy images. However, GRN-5 in both
redox states (GRN-5 and rGRN-5) showed
exponential fluorescence recovery immediately
after incubation indicating fluid property of the
droplet (Fig 4i and 4j; 0h). After 36h, the extent of
recovery was slightly mitigated indicating a
possible “gelation” of the droplet (Fig 4i and 4j;
36h). Together, the data further confirm that both
GRN-5 and rGRN-5 induce LLPS with TDP-43
CTD by coacervation. On the other hand, GRN-3
does not induce LLPS but forms insoluble deposits
of aggregated forms of TDP-43 CTD, indicating the
differential specificity for the two GRNs in
interacting with TDP-43 CTD. In other words, both
GRNs could initiate different biophysical
processes; while the presence of GRN-3 or rGRN3 lead to insoluble aggregates, those of GRN-5 or
rGRN-5 result in the droplet formation that could
change to gelation or aggregates over time.

However, the samples showed distortions in the
morphology of LDs accompanied by an overall
reduction in the size during the course of the
experiment (Fig 6e-f). Addition of GRN-5 to TDP43 CTD-RNA mixture also showed the formation
of droplets immediately with GRN colocalized
within the droplets, which fused and grew bigger in
size during the next 36 hours, with both TDP-43
CTD and GRN-5 colocalizing within the LDs (Fig
6g). Addition of rGRN-5 to TDP-43 CTD-RNA
mixture led to droplet formation which grew in
number but not in size during the same time (Fig
6h). rGRN-5 also co-localized with TDP-43 CTD
within the LDs.
To probe the internal dynamics of the LD
droplets, FRAP was monitored temporally on
labelled TDP-43 CTD in presence of RNA and
GRNs. The fluorescence recovery rates for the
control LDs formed by TDP-43 CTD and RNA
showed near identical rates at both 0 and 36 hours,
indicating preservation of internal mobility and
dynamism over the incubation period (Fig 6i). LDs
formed in the presence of either GRN-3 or rGRN-3
showed a marked level of decrease in the internal
mobility of the droplets during the 36 hours of
incubation (Fig j-k). Similarly, LDs formed in
presence of both redox forms of GRN-5 displayed
a decreased fluorescence recovery after 36 hours
indicating an inhibition of internal mobility, which
could indicate the maturation of the droplets into
gels, process commonly known as ‘gelation’ (Fig
6l; GRN5 and Fig 6m; rGRN-5). Similar to the
observation of GRN-5 and TDP-43 CTD where
‘gelated’ droplets eventually transition to solid
aggregates (Fig S2), it is possible that these
‘gelated’ LD also eventually form insoluble
aggregates of TDP-43 CTD. The increase in ThT
fluorescence (Fig 6c) can be explained by the fact
that ThS (and likely ThT) is able to partitions into
the droplets and fluoresces as observed (Fig 3). The
results obtained suggest that both GRNs 3 and 5 in
redox conditions co-localize and stabilize the LDs
formed by TDP-43 CTD and RNA. What cellular
ramifications this may have on stress response by
stress granules is remains to be seen.
DISCUSSION
Link between PGRN and familial FTLD/ALS
is well-established with the implication of
autosomal dominant mutations in PGRN, which
leads to the protein’s haploinsuffiency. The loss of
7

Downloaded from http://www.jbc.org/ at University of Southern Mississippi on February 10, 2020

incubated with TDP-43 CTD in the presence or
absence of GRNs. As expected, control LDs
containing a mixture of 20 µM TDP-43 CTD and
40 µg/mL RNA showed high turbidity (Fig 6a).
Solutions containing a mixture of LDs and 40 µM
of GRN-5 showed an increase in turbidity as
compared to LD control (Fig 6a). The sample
containing 40 µM rGRN-5 and LDs did not show
appreciable change in turbidity. Similarly, solutions
containing a mixture of LDs and GRN-3 or rGRN3 showed a slight decrease or no change turbidity
levels as compared to the control (Fig 6a). In order
to see how GRNs affect the formation of ThTpositive inclusions of the LDs, the reactions were
monitored by ThT fluorescence (Fig 6b-c). As
expected, the co-incubation of RNA with TDP-43
CTD did not show any ThT increase as they form
LDs (Fig 6b and Fig 6c) as compared to the TDP43 CTD alone (; Fig 6b and Fig 6c). Inclusion of
rGRN-3 to the RNA and TDP-43 CTD mixture
significantly increased the rate of ThT-positive
aggregates of TDP-43 CTD (Fig 6b) but slightly
delayed the aggregation compared to TDP-43 CTD
alone or with rGRN-3 (Fig 6b). Similar
augmentation of aggregation was observed with the
co-incubation of GRN-3 and TDP-43 CTD-RNA
mixture (Fig 6b) although the increase in rate of
aggregation was less pronounced with GRN-3 as
compared to rGRN-3 as previously observed in Fig
3. Co-incubation of rGRN-5 to the TDP-43 CTDRNA mixture ‘rescued’ the aggregation of TDP-43
CTD with a linear increase in ThT fluorescence
observed within hours of incubation (Fig 6c).
However, augmentation of ThT-positive aggregates
was also pronounced with the co-incubation of
GRN-5 (Fig 6c). These data indicate that GRNs are
able to modify LD to promote aggregates of TDP43 CTD.
To further understand the mechanism of GRNs’
influence on LD, co-incubations of fluorescentlytagged samples were monitored by DIC
microscopy. As expected, TDP-43 CTD-RNA
showed LD formation immediately after incubation
that remained for 36 hours (Fig 6d). Co-incubation
of GRN-3 or GRN-3 with the mixture of TDP-43
CTD and RNA showed neither a marked change to
the droplet shape or size nor the GRN colocalized
within the droplet (Fig 6e-f). After 36 hours, a
marginal increase in LD size was observed with
GRN colocalized within the droplets (Fig 6e-f).

EXPERIMENTAL PROCEDURES
Expression and purification of recombinant
proteins
Granulins (GRN-3 & GRN-5): Unlabeled
GRN-3 was expressed and purified from E. coli
SHuffleTM cells (New England Biolabs) as
described previously (62), while unlabeled GRN-5
and 15N labeled GRN-5 were expressed in Origami
2 DE3 (Invitrogen). Briefly, the proteins were
expressed as a GRN:trxA fusion construct and
purified using immobilized-nickel affinity
chromatography. The fusion protein was then
cleaved by addition of restriction grade thrombin
8
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results provide the first in vitro evidence for an
interaction between GRN and TDP-43 CTD.
The increasing relevance of GRNs in FTLD
and associated neurodegenerative disorders imparts
significance to the results presented in this study.
Despite its significance, how haploinsufficiency of
PGRN results in TDP-43 inclusions in FTLD and
ALS patients remains unknown. Common
mutations
associated
with
PGRN
haploinsufficiency have been linked to mutant
mRNA degradation (88) which several groups have
identified leads directly to reduced circulating
levels of PGRN (89-91). A few have also argued
that increased proteolysis of PGRN as the reason
for haploinsufficiency, which leads to increase in
GRN levels (57). A more recent study established
that more effective proteolytic processing of
cathepsin D, an aspartyl protease that is known to
cleave PGRN, occurs in the presence of GRNs (92),
which seem to support the idea that generation of
GRNs to be the reason for decreased availability of
PGRN. Results presented in this study identify a
potential mechanism by which GRNs interact with
TDP-43 CTD and modulate the latter’s ability to
aggregate and/or phase separate (Fig 6). Based on
our data we can hypothesize that the selective
GRNs interact with free TDP-43 CTD to augment
its aggregation and potentially its cytotoxicity.
Alternatively, under redox stress, GRNs can
interact with LDs to modulate the dynamics within
the droplets towards the formation of insoluble
inclusions or lead to a decreased stress response.
These aspects, along with whether and how these
processes are regulated by phosphorylation and
other mutations within GRNs and TDP-43 are
currently being investigated in our laboratory, and
the results obtained will be reported at a later time.

PGRN function in these pathologies is also
speculated to arise at a posttranscriptional level
with increased PGRN proteolysis (82). GRN
immunopositivities have indeed been observed in a
region-specific manner in both AD and FTLD
human brains (83). Furthermore, the production of
GRNs in haploinsufficient and not null state in
familial FTLD suggests that they may be key
players in the disease phenotypes. Support for this
thought comes from the observation that GRNs
interact with TDP-43 and exacerbate latter’s levels
and toxicity in C.elegans (57). Moreover, the recent
discovery of PGRN/GRNs being associated with
lysosomal dysfunction (84) also posits the question
whether GRNs could be involved in autophagic fate
of TDP-43 inclusions under redox stress. The
results presented here attempts to answer some of
the key questions regarding GRNs and TDP-43
CTD such as how GRNs modulate the dynamics
between LD and fibril formation of TDP-43 CTD
and do LDs facilitate the formation of insoluble
TDP-43 CTD inclusions.
The findings of this study showcase how GRNs
-3 and -5 modulate the dynamics of TDP-43 CTD
in forming insoluble aggregates or LDs in both
oxidizing and reducing conditions. It is clear from
the data that GRN-3 and GRN-5 affect TDP-43
CTD aggregation via disparate mechanisms; while
GRN-3 induces the formation of insoluble
inclusions, GRN-5 coacervates with TDP-43 CTD
to undergo LLPS in both reduced and oxidized
forms, an interaction which is likely to be driven by
the counter-ionic electrostatic characteristics of
TDP-43 CTD and the negatively charged GRN-5
(85-87). Furthermore, GRN-3 and GRN-5 also
modify LDs formed by the coacervation of RNA
and TDP-43 CTD. Specifically, GRN-3 in both
redox states accelerate the formation of ThTpositive, insoluble aggregates of TDP-43 CTD.
This observation supports the one by Salazar and
co-workers who observed exacerbation of TDP-43
toxicity in C.elegans by GRN-3 and GRN-7 (57).
GRN-5, on the other hand seems to remodify the
LDs by inducing gelation within the 36-hour time
period, which changes to fibril formation after
extended time period (supplementary Fig S2). At
this point, it is unclear as to what cellular
ramifications do the gelation of LDs by GRN-5
have, but our on-going investigations will glean
into this aspect in the future. Nevertheless, our

500 mM NaCl, 6 M Urea, 150 mM imidazole).
Eluate was buffer exchanged into storage buffer (20
mM Tris pH 8.0, 500 mM NaCl, 2 M Urea) and
concentrated using Amicon Ultra-Centrifugal units
(Millipore). Concentrated protein was flash frozen
and stored at -80°C. Concentrated aliquots were
thawed on ice and desalted into 20 mM MES pH
6.0 using Zeba Desalting Spin Columns (Thermo)
and used as such for studies.
Thioflavin-T fluorescence
The aggregation kinetics of TDP-43 CTD were
monitored using Thioflavin-T (ThT) on a BioTek
Synergy H1 microplate reader. 20 μM TDP-43
CTD under varying reaction conditions was
incubated at 37°C for 36 hours in presence of 10
μM ThT. Samples were excited at 440 nm and
emission was monitored at 480 nm. The ThT
kinetic data was fit using the Boltzmann function
on Origin 8.5.
MALDI-ToF
mass
spectrometry
Pellet and droplet characterization of the coincubated protein complexes was performed on a
Bruker Datonics Microflex LT/SH ToF-MS
system. Samples from aggregation kinetic reactions
were recovered after a period of 36 hours. The
recovered samples were spun down at 18000 xg and
supernatant was decanted. The pellet obtained was
then resuspended in equal volume of reaction buffer
(20 mM MES, pH 6.0). The pellet and supernatant
fractions were then prepared for MALDI-MS by
mixing with 6.5 ng of insulin (external standard).
Additionally, the pellet samples were dissolved
with formic acid in a 1:1 ratio to allow
disaggregation of fibrils and other insoluble
complexes. Both aliquots were then spotted onto a
Bruker MSP 96 MicroScout Target with 1:1 ratio of
sample:sinapinic acid matrix in saturated
acetonitrile and water. Instrument calibration was
performed using Bruker Protein Calibration
Standard I (Bruker Daltonics).
Differential Interference Contrast (DIC)
The phase separation was monitored using DIC
on a Leica DMIL LED microscope under 20x or
40x magnification with a DIC polarizing filter. The
reactions were observed on a clear-bottom Nunc™
MicroWell™ 96-Well Microplates (Thermo).
Fluorescence microscopy
9
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(Bovine, BioPharm Laboratories) at 1U per 1 mg of
the protein to remove both trxA and the His-tag.
The reaction was incubated at room temperature
(~25°C) for 22-24 hours. The protein was then
fractionated on a semi-preparative Jupiter® 5 μm
10x250 mm C18 reverse phase HPLC column
(Phenomenex), using a gradient elution of 60 – 80
% acetonitrile containing 0.1% TFA as previously
described (62). The concentration of the proteins
was estimated spectrophotometrically using molar
extinction coefficients of 6250 M-1cm-1 for GRN-3
and 7740 M-1cm-1 for GRN-5 at 280 nm. The
number of free cysteines was calculated from
Elman’s assay and by iodoacetamide labeling as
previously reported (62). rGRN-3 and rGRN-5
were generated by the addition of 2 mM Tris(2carboxyethyl)phosphine hydrochloride (TCEP) to
the HPLC fractionated protein for 2 hours at room
temperature and were used as the reduced form. 15N
labeled GRN-3,5 were generated by growing the
cells in M9 minimal media enriched with 15NH4Cl.
TDP-43 CTD. The plasmid for the TDP-43
CTD expression was a gift from Dr. Nicolas Fawzi
at Brown University (Addgene plasmid # 98669;
http://n2t.net/addgene:98669;
RRID:Addgene
98669). The protein was expressed as a fusion
construct with a His-tag (His6) at the N-Terminal
followed by a TEV cleavage site The plasmid was
expressed in E.coli BL21 Star™ (DE3) cells (Life
Technologies). Transformed cells were grown at
37°C in LB medium supplemented with 100μg/ml
of kanamycin. Overexpression of the protein was
induced
by
adding
isopropyl
β-D-1thiogalactopyranoside (IPTG) to a final
concentration of 0.5 mM at an optical density
(O.D600) of 0.5-0.7 AU. After overnight induction
at room temperature (~25°C), cells were harvested
by centrifugation (15000xg, 4 °C) and used
immediately or stored at −20°C. The cells were
resuspended in lysis buffer (20 mM Tris pH 8.0,
500 mM NaCl, 5 mM imidazole, 6 M urea). 0.5 mM
phenylmethylsulfonyl fluoride (PMSF) was also
added to the resuspension. Cells were lysed using
Misonix XL-2000. The lysate was centrifuged at
20000 xg, 4°C, for 1 hour to remove cellular debris.
The supernatant was incubated with Ni-NTA resin
at 4°C for 2 hours. The slurry was resuspended in
Kimble Kontes Flex column and washed with wash
buffers (20 mM Tris pH 8.0, 500 mM NaCl, 6 M
Urea) of 15 mM and 30 mM imidazole and protein
was eluted in elution buffer (20 mM Tris pH 8.0,

The HMQC NMR spectra for 20 μM 15N GRN5 or rGRN-5 resuspended in 20 mM MES (pH 6.0)
with 10% D2O was acquired on a Bruker Advance
– III-HD 850 MHz NMR spectrometer equipped
with a Bruker TCI cryoprobe at the high field NMR
facility of University of Alabama, Birmingham as
described previously(62).
Computational analysis of TDP-43 CTD, GRN-3,
and GRN-5
Per-residue intrinsic disorder predispositions of
TDP-43 CTD, GRN-3, and GRN-5 were evaluated
by a set of commonly used disorder predictors, such
as PONDR® VLXT(93) , PONDR® VSL2 (94) , and
PONDR® VL3 (95) available on the PONDR site
(http://www.pondr.com) PONDR® FIT (96)
accessible
at
the
DisProt
site
(http://original.disprot.org/metapredictor.php), and
the IUPred computational platform available at
IUPred2A site (https://iupred2a.elte.hu/) that
allows identification either short or long regions of
intrinsic disorder, IUPred-L and IUPred-S (97100). For each query protein, the outputs of these
individual predictors were used to calculate a
consensus disorder profile by averaging disorder
profiles of individual predictors. The outputs of
these tools are represented as real numbers between
1 (ideal prediction of disorder) and 0 (ideal
prediction of order). A threshold of ≥0.5 was used
to identify disordered residues and regions in query
proteins. A protein region was considered flexible,
if its disorder propensity was in a range from 0.2 to
0.5. Results of this multiparametric computational
analysis are presented in a form of mean disorder
propensity calculated by averaging disorder
profiles of individual predictors. Use of consensus
for evaluation of intrinsic disorder is motivated by
empirical observations that this approach usually
increases the predictive performance compared to
the use of a single predictor (96,101-108). CIDER
computational platform (65) was used to generate
linear net charge per residue diagrams for query
proteins, whereas the sequence-based propensities
of TDP-43 CTD, GRN-3, and GRN-5 for granule
formation associated to liquid demixing under the
physiological conditions were evaluated by
CatGRANULE algorithm (68) , which generates
positive and negative scores for proteins capable
and not capable of granule formation, respectively.
Finally, the presence of disorder-based binding

FRAP
FRAP assays were performed in open-ended 96
well plates as described above; 10 μM TDP-43
CTD was mixed with 20 μM GRN-3,5 or 20 μg/mL
of RNA. Reactions were monitored 10 mins after
mixing to allow deposition of suitable droplets onto
the bottom of the well, which were used for
bleaching. TDP-43 CTD labelled with HiLyte-647
(AnaSpec) was used as the probe in the assays.
LSM 510 Meta confocal microscope at 63x
magnification under oil-immersion with a DIC
polarizing filter and FRAP module. The region of
interest was bleached with 633 nm laser line with
100% bleaching intensity for 750 iterations and
imaging was performed at 5% laser intensity for
120 secs after bleaching. Numerical aperture was
kept at 0.69 AU.
NMR spectroscopy
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For colocalization studies of GRNs and TDP43 CTD during the course of their interactions,
labeling of the respective proteins with aminereactive fluorescent dyes was performed and
visualization was done on a Zeiss LSM 510 Meta
confocal microscope at 40x or 63x magnification
under oil-immersion with a DIC polarizing filter.
Briefly, TDP-43 CTD was labelled with HiLyte647 (AnaSpec) and GRN-3,5 were labelled with
HiLyte-405 (AnaSpec). Free dyes were removed
via the use of desalting columns; Zeba Desalting
Spin Columns (Thermo) for labeled TDP-43 CTD
and Clarion™ MINI Spin Columns, Desalt S-25
(SorbTech) for labeled GRN-3,5. 20 uM TDP-43
CTD was mixed with 40 μM GRN-3,5 or 40 ug/mL
of RNA. A ratio of 1% Labeled: 99% Unlabeled
proteins was used for both TDP-43 CTD and
GRNs. Reactions were performed on the following
experimental setup: A glass cover-slip was attached
onto one end of a two-side open ended 96 well plate
(Greiner Bio-One). Reactions were loaded into a
well and covered with an optically clear platesealing film (Thermo). Reactions were then
monitored at certain timepoints. Similarly, for
observing the localization of ThS, 10 μM ThS
(AAT bioquest) was added to sample containing 20
μM TDP-43 CTD with 40 µM of GRNs. Samples
were visualized using the setup described above on
a Zeiss LSM 510 Meta with 420-480 band pass
emission filter

sites in TDP-43 CTD was evaluated by the
ANCHOR algorithm (66,67).
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Fig 1: Sequence, disorder and charge distributions of the proteins used in this study. a) The
sequence of TDP-43 C-terminal domain (TDP-43 CTD) (267-414; 14.5 kDa) which constitutes
the major part of the toxic 25 kDa TDP-43 C-terminal fragment with a hexa histidine-tag on the
N-terminus. Sequences of GRN-3 and GRN-5 with putative disulfide bonds. A conservative
mutation of Y to W (indicated as *) was made to GRN-3, which is a conserved residue in all
GRNs. Both GRNs were used in fully reduced (free thiols) and oxidized conditions in this study.
Computational evaluation of the per-residue intrinsic disorder predispositions of TDP-43 CTD
(b), GRN-3 (c), and GRN-5 (d). Here, the outputs of PONDR® VLXT, PONDR® FIT,
PONDR® VL3, PONDR® VSL2, IUPred_S and IUPred_L were averaged to generate mean
disorder profiles of different computational data query proteins. Diagrams of linear net charge
per residue (NCPR) for TDP-43 CTD (e), GRN-3 (f), and GRN-5 (g) generated by CIDER
computational platform (http://pappulab.wustl.edu/CIDER/).
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Fig 2: TDP-43 CTD undergoes LLPS in the presence of both oxidized and reduced GRN-5.
a) Visual snapshots immediately after the incubations of 20 µM TDP-43 CTD in 20 mM MES
buffer pH 6.0 without salt at room temperature by itself or with 40 µM GRNs in oxidized (GRN3; GRN-5) and reduced (rGRN-3; rGRN-5) conditions along with the positive control with 40
µg/mL RNA. Only incubations with GRN-5, rGRN-5 and RNA show a turbid solution indicating
phase separation. b) DIC microscopy images for the same reactions monitored for 6 hours. TDP43 CTD by itself or with GRN-3/rGRN-3 shows the absence of liquid droplets which those with
GRN-5 or rGRN-5 coalescence of the droplets to varying degrees similar to the positive control
(with RNA) confirming LLPS. Scale bar represents 50 µm. c-h) Phase diagrams for TDP-43 CTD
LLPS under various conditions. Phase boundary is represented by lines while grey box represents
the conditions where LLPS was observed. c) LLPS of 20 µM TDP-43 CTD as a function of
increasing GRN concentrations in the absence of salt. d-h) Phase diagrams for 20 µM TDP-43
CTD as a function of increasing salt and GRN concentrations for GRN-3 (e), rGRN-3 (f), GRN-5
(g) and rGRN-5 (h) along with control TDP-43 CTD in the absence of GRN (d). All phase
diagrams were obtained from the turbidity of the reactions measured at 600 nm within ten minutes
of incubation. The color gradient representing LLPS was generated by normalizing the absorbance
values against 0-100% of black color gradient. A turbidity value of 0.11 A.U was taken as a cutoff
LLPS.
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Fig 3: Modulation of TDP-43 CTD aggregation by GRNs. a-d) The aggregation kinetics of
20µM TDP-43 CTD in 20 mM MES buffer pH 6.0 at 37 °C with varying molar equivalence (2 to
80 µM) of GRN-3 (a), rGRN-3 (b), GRN-5 (c) and rGRN-5 (d), monitored by thioflavin-T (ThT)
fluorescence. The inset shows the enlarged areas (boxed with dashed lines) highlighting the lag
times during aggregation. The data was fitted to Boltzmann sigmoidal function. e-h) Localization
of the aggregate-specific dye, thioflavin-S (ThS) observed by confocal fluorescence microscopy
images on the 1:2 reaction samples of TDP-43 CTD:GRN from a-d immediately (0h) and after 36
hours of incubation. (i) Images of TDP-43 CTD control from the reaction in (a). Scale bar
represents 20 µm and brightfield view is denoted by Bf.
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Fig 4: Coacervation of GRNs with TDP-43 CTD and dynamics of LLPS. Localization of TDP43 CTD and GRNs was monitored on a co-incubated mixture of the two proteins in 1:2 molar
ratio. A mixture containing 0.2 µM (1%) aliquot of TDP-43 CTD labeled with HiLyte 647
fluorescent tag and 20 µM unlabeled TDP-43 CTD in 20 mM MES buffer pH 6.0 at 37 °C, was
co-incubated with a mixture of 40 µM GRNs containing 1% of respective proteins labeled with
HiLyte 405 in separate reactions. Each of the co-incubated mixtures were visualized using DIC
microscope. ‘Bf’ represents bright field in all the images. a) TDP-43 CTD control in the absence
of GRNs shows formation of fibrillar structures after a period of 18 hours that increase in size after
36 hours. TDP-43 CTD co-incubated with GRN-3 (b) or rGRN-3 (c) show colocalization within
the inclusions as well as some peripheral localization. Co-incubated samples containing GRN-5
(d) or rGRN-5 (e) show co-localization with TDP-43 CTD within droplets formed by LLPS. Scale
bars in a-e represent 20 µm. f-j) Fluorescence recovery after bleaching (FRAP) performed using
HiLyte 647 labeled-TDP-43 CTD. Arrow represents the time of bleaching. f) Aggregates formed

by TDP-43 CTD control show no fluorescence recovery after 36 hours. g-h) fluorescence recovery
for samples containing GRN-3(g) or rGRN-3(h) immediately (0 h; black) or after 36 h of
incubation (red). i-j) fluorescence recovery for samples containing GRN-5 (i) or rGRN-5 (j)
immediately (0h; black) and after 36 h of incubation (red). The confocal images in the insets in fj show the area bleached before, after, and after recovery from left to right. Scale bar represents 2
µm.
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Fig 5: Quantitation of sedimented droplets and pellets from the co-incubations of TDP-43
CTD and GRNs. The co-incubated samples of TDP-43 CTD and GRNs from figures 3 and 4 were
sedimented at 18,0000xg for 20 minutes after 36 hours of incubation, and the pellets were
quantified by MALDI-Tof mass spectrometry using insulin (6.45 ng/µL, m.w 5733.9 Da) as an
external standard. The amounts of GRN-3 (mw 6367.3 Da), GRN-5 (mw 6015.7 Da) or TDP-43
CTD (mw 17008.1 Da) within the pellets were determined with respect to the standard (detailed
in Materials and Methods) and plotted as a ratio of GRN to TDP-43 CTD for the respective molar
ratios. a-e) MALDI-ToF spectra of samples containing 20 uM TDP-43 CTD with 40 µM of GRN3 (a), rGRN-3 (b), GRN-5 (c), rGRN-5 (d) and TDP-43 CTD control (e) Theoretical and observed
molecular weights are shown within and outside parentheses, respectively. f-i) Ratio of intensity
23

of GRNs present in complex with TDP-43 CTD in samples of varying molar ratios of the former
shows an increase of GRN-3 (e) and rGRN-3 (f) within the complexes at higher molar ratios, while
GRN-5 (g) and rGRN-5 (h) are present in a constant amount. GRN-5 forms a 1:1 complex with
TDP-43 CTD in both redox forms; GRN-5 (0.73) and rGRN-5 (1.1) as indicated by the average
amount (dashed line).

Downloaded from http://www.jbc.org/ at University of Southern Mississippi on February 10, 2020

Fig 6: Modulation of TDP-43 CTD-RNA LDs by GRNs. a) Turbidity measured at 600 nm within
ten minutes of incubation for the co-incubated solutions of 20 µM TDP-43 CTD with 40 µM GRN3 or 5 (reduced and oxidized), in the presence or absence of 40 µg/mL of RNA (n=3). b-c)
Aggregation kinetics of 20µM TDP-43 CTD in 20 mM MES buffer pH 6.0 at 37 °C with 40 µM
of GRN-3 (b) and GRN-5 (c) in both oxidized and reduced forms, and in presence or absence of
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Fig 7: Schematic of the data presented in this study. GRNs selectively modulate the dynamics
of TDP-43 CTD aggregation or phase separation, which may have physiological implications. The
question marks indicate in this figure are possibilities unexplored in this manuscript.
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RNA (40 µg/mL) monitored by ThT fluorescence. The inset shows the enlarged areas (boxed with
dashed lines) highlighting the lag times during aggregation. d-h) Localization of the protein from
the reactions similar to those in panels b and c visualized by labeling TDP-43 CTD and GRNs with
HiLyte 647 and HiLyte 405, respectively (as it was done for Fig 4), and in the presence and absence
of unlabeled RNA by DIC microscopy. Control sample containing TDP-43 CTD and RNA shows
LDs (d). GRN-3 (e) or rGRN-3 (f) do not localize within LDs but form solid inclusions but GRN5 (g) or rGRN-5 (h) colocalize within the LDs. Scale bars in d-h represent 20 µm. j-m) FRAP data
using HiLyte 647-labeled TDP-43 CTD with LDs and GRNs immediately after incubation (0 h;
black) and after 36 hours (red). Arrow represents the time of bleaching. Fluorescence recovery for
samples containing control LDs(i), GRN-3(j), rGRN-3(k), GRN-5 (l) or rGRN-5 (m). The insets
in i-m show confocal images of the area bleached before, after, and after the recovery from left to
right. Scale bar represents 2 µm.
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